The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…
Last Updated 2 November 2015 Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year…
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)…
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies? The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming…
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…
As the Relapsed/Refractory Treatment Setting for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to…